| Literature DB >> 32253231 |
Aravind S Ravi Kumar1,2, Michael S Hofman1,2.
Abstract
PSMA radioligand therapy is a promising new class of therapy for prostate cancer. Heterogeneity of PSMA expression is an important factor explaining variability in clinical results. The ability to visualize the target with theranostics provides unique mechanistic insights. Potential clinically applicable strategies to improve patient selection and optimize therapeutic efficacy are discussed.See related article by Current et al., p. 2946. ©2020 American Association for Cancer Research.Entities:
Mesh：
Year: 2020 PMID： 32253231 DOI： 10.1158/1078-0432.CCR-20-0209
Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531